A Trial of Procalcitonin in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Procalcitonin, Chronic Obstructive Pulmonary Disease
About this trial
This is an interventional treatment trial for Procalcitonin
Eligibility Criteria
Inclusion Criteria:
- Hospitalized patients with AECOPD
- ≥40 years of age
- Able to understand and communicate to ensure the completion of the trial
- Voluntary participation and provide written informed consent
Exclusion Criteria:
- Fever, Axillary temperature≥38°C
- Pneumonia identified by X-Ray or CT of the chest
- Severe respiratory failure requiring admittance to ICU
- Concurrent infection at another site (e.g. urinary tract infection)
- Immunosuppression secondary to chemotherapy, AIDS or malignant tumor of blood system
- Comorbidities requiring corticosteroids (prednisone 30mg/d or equivalent more than 30 days )
- Invasive mechanical ventilation
- Patients with malignant tumors receiving chemotherapy or radiotherapy
- Pregnancy
- Participation in another clinical trial
- Previously enrollment into the study
- Refuse to attend
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
PCT-guided antibiotic therapy (PCT group)
Guideline-guided antibiotic therapy (guideline group)
Participants in the PCT group will complete a PCT test within 2 hours after randomization and the results will be sent back to the clinician by laboratory through the internal network of the hospital. The prescribing clinician will use the results of the PCT to help guide their antibiotic prescription decision. The detailed recommendations are as follows: if PCT<0.1ng/ml,strongly discouraged;if PCT (0.1-0.25ng/ml) and no sputum purulence, discouraged; if PCT (0.1-0.25ng/ml) and sputum purulence, Recommended; PCT>0.25 ng/ml, Strongly recommended.
Participants in the guideline group will also need to complete a PCT test within 2 hours after randomization, however, the laboratory will save the results and do not sent back to the clinician. The clinician will make an antibiotic prescribing decision on the basis of the recommendations of GOLD guideline. The guideline recommend the following patients to receive antibiotic therapy. Patients with exacerbations of COPD who have three cardinal symptoms: increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).